Lilly opens big R&D center in Boston’s Seaport District

Eli Lilly's Lilly Seaport Innovation Center

Edited from a New England Council report

On Aug. 13,  Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research-and-development facility in Boston’s Seaport District dedicated to furthering the company’s efforts in RNA and DNA-based therapies and discovering new drug targets to create transformative medicines for a range of conditions.

Lilly aims to use innovative biotechnology and medicine to create solutions to major health challenges. The new site will house the first Lilly Gateway Labs location on the East Coast, encouraging a culture of shared expertise and real-time learning to promote the development of novel medicines.

“The opening of LSC expands upon Lilly’s long-standing presence in the Boston area,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology. ‘‘We are committed to being supportive neighbors in this hub of discovery and innovation, furthering collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them the most.”